The relatively new science of pharmacogenomics is getting an increasing amount of attention as of late. According to the NIH, it is defined, somewhat simply, as “the study of how genes affect a person’s response to drugs.” It was born out of the fact that current drugs on the market are designed to essentially be a “one-size-fits-all” solution to a particular health problem. However, anyone who has had the patience to sit through the list of disclaimers in a drug commercial or strained their eyes reading the litany of potential side effects a pharmaceutical might have understands that drugs affect different people in different ways, despite their having the same condition. Some may experience the relief they seek, fulfilling the purpose of the drug with little to no ill side effects, while others may experience significant adverse conditions, including (rarely) death. The study of pharmacogenomics presumes that this is likely due to sequence variants in the patients’ genes.
You might notice a preponderance of people wearing purple this month. That’s because it’s the signature color of the Alzheimer’s Association’s “Go Purple” initiative to raise awareness about the devastating effects of the disease. Discovered by Dr. Alois Alzheimer in 1906, the disease is defined by the National Institute on Aging (NIA) as “an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.” It is estimated that more than 5 million Americans may have Alzheimer’s, and that it may rank as the third most common cause of death for older people, superseded only by cancer and heart disease.
We have reached the end of our 4-part series! We hope you and your fellow supply chain and value analysis professionals found the information useful and have shared it with your peers. Don’t forget, you can also download our free eBook, Evidence: The 5th Domain of Value-Based Purchasing to read the content of this series in one complete package.
Didn’t read part 3? Here’s part 3.
Without further ado, we will review our fourth and final VBP domain as well as talk about the link between evidence and executive compensation.
The quagmire that is the American healthcare system continues to leave payers, providers, and patients wringing their hands with the uncertainty of what lies ahead. Tired of waiting for the other shoe to drop and unwilling to leave their valuable employees without the coverage they need for themselves and their families, some companies have gone the self-funded, self-insured route. This path, while innovative and admirable, is not without complications and is not entirely immune from the current issues swirling around healthcare reform.
Welcome back for part 3 of our 4-part series! We’re just past the halfway mark in our effort to tell you about the impact of evidence on value-based purchasing (VBP). If you found the previous installments informative, please share these blogs with your fellow supply chain and value analysis professionals. Don’t forget, you can also download our free eBook, Evidence: The 5th Domain of Value-Based Purchasing to read the content of this series in one complete package.
Need to catch up? Here’s part 2.
Let’s review our third VBP domain: Clinical Care (Outcomes and Process).
We are pleased to announce our lineup of guest speakers for this year’s Client Symposium. In addition to our keynote speaker, we are featuring two professionals who bring years of healthcare expertise and experience to our second annual gathering in the city of brotherly love.
The credentials of these sought-after presenters speak for themselves, so I’m going to let them do just that. Once you’ve read about their impressive backgrounds and accomplishments, head over to our registration page and reserve your spot at the Client Symposium today!
Last week, as part of their “Your Health” segment, NPR aired a piece about the effectiveness of various treatments for low back pain, with a focus on spinal manipulation. Lower back pain is a common complaint to physicians, and, as the article states, a common reason for the prescription of addictive narcotic painkillers. Other interventions can include:
- Physical therapy
- Massage therapy
- Nonsteroidal anti-inflammatory drugs (NSAIDS)
- Chiropractic treatment
Hayes is a company of real people and we’d like you to get to know us. This month, we introduce you to another valuable contributor to the Hayes mission of providing fiercely unbiased evidence. Meet Beth Bontemps.
Ms. Bontemps joined Hayes in September 2014 as a Senior Analyst. In 2017, she was promoted to the position of Product Manager, Prognosis and News Service.
She comes to Hayes from JR Associates Inc., a medical technology reimbursement consulting firm where she worked as a clinical and reimbursement consultant.
Topics: Hayes Blog
Who doesn’t love lists? Especially lists detailing the best of the best, the most popular, the most in-demand. To that end, we’ve compiled a list of our top three Directory reports for the first three months of the year, in order of retrievals from our Knowledge Center. These three represent a mix of information important to both payers and providers.
If you’re already a subscriber, you can check out these reports at any time. If you’re not a Hayes member…what are you waiting for? Don’t forget, you can also purchase an individual report. Contact us to find out how.
Let’s get to the top three!
Last week, I had the distinct privilege of presenting the keynote at the first annual Northeast Regional Conference of the Association of Healthcare Value Analysis Professionals (AHVAP). With the ever-increasing push away from fee-for-service and toward value-based healthcare, I thought it pertinent to discuss the role of value analysis in the success of a health system’s bundled payment initiatives. Specifically, I wanted to highlight the role evidence can play in assisting value analysis professionals in their evidence-based decision making, as well as how it can help them define the part they play in the value-based purchasing environment.